Page last updated: 2024-10-28

hydralazine and Parkinson Disease, Secondary

hydralazine has been researched along with Parkinson Disease, Secondary in 1 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vaidya, RA1
Vaidya, AB1
Van Woert, MH1
Kase, NG1

Other Studies

1 other study available for hydralazine and Parkinson Disease, Secondary

ArticleYear
Galactorrhea and Parkinson-like syndrome: an adverse effect of alpha-methyldopa.
    Metabolism: clinical and experimental, 1970, Volume: 19, Issue:12

    Topics: Adolescent; Amenorrhea; Female; Glomerulonephritis; Humans; Hydralazine; Hypertension; Kidney Transp

1970